Document is current

Article History

Accepted: 13 January 2023

First Online: 3 March 2023

Compliance with Ethical Standards

:

: Mia C. Weiss declares that she has no conflict of interest. Brian A. Van Tine reports personal fees from Polaris and personal fees from Adaptimmune, outside the submitted work; in addition, Dr. Van Tine has a patent Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766) licensed to Accuronix Therapeutics, a patent Modular Platform for Targeted Therapeutic Delivery (006755) licensed to Accuronix Therapeutics, and a patent Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synthesis and Uses Thereof (014229) pending to Accuronix Therapeutics.

: This article does not contain any studies with human or animal subjects performed by any of the authors.